Immunotherapy and naturally occurring autoantibodies in neurodegenerative disorders

Autoimmunity Reviews

Volumn 7, Issue 6, 2008, Pages 501-507

  Neff, Frauke ^a   Wei, Xing ^b   Nölker, Carmen ^a   Bacher, Michael ^a   Du, Yansheng ^a,b   Dodel, Richard ^a  

^a PHILIPPS UNIVERSITY MARBURG   (Germany)

^b INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Alzheimer's disease; Creutzfeld Jakob disease; Immunotherapy; Naturally occurring autoantibodies; Parkinson's disease

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; ALPHA SYNUCLEIN; AMYLOID BETA PROTEIN; AMYLOID BETA PROTEIN[1-42]; ATAXIN 1; AUTOANTIBODY; BETA SYNUCLEIN; COPPER ZINC SUPEROXIDE DISMUTASE; GAMMA SYNUCLEIN; HUNTINGTIN; IMMUNOGLOBULIN; PRION PROTEIN; TAU PROTEIN;

ACTIVE IMMUNIZATION; ALZHEIMER DISEASE; BLOOD BRAIN BARRIER; CREUTZFELDT JAKOB DISEASE; DEGENERATIVE DISEASE; GERSTMAN STRAUSSLER SCHEINKER SYNDROME; HISTOPATHOLOGY; HUMAN; IMMUNOTHERAPY; LEWY BODY; NONHUMAN; PARKINSON DISEASE; PASSIVE IMMUNIZATION; PATHOPHYSIOLOGY; PHAGOCYTOSIS; REVIEW; TRANSGENIC MOUSE; WESTERN BLOTTING;

ALPHA-SYNUCLEIN; ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; ANIMALS; AUTOANTIBODIES; CREUTZFELDT-JAKOB SYNDROME; HUMANS; MICE; NEURODEGENERATIVE DISEASES; PARKINSON DISEASE; PRIONS;

EID: 51749097108     PISSN: 15689972     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.autrev.2008.04.010     Document Type: Review

References (40)

1. Skovronsky D.M., Lee V.M., and Trojanowski J.Q. Neurodegenerative diseases: new concepts of pathogenesis and their therapeutic implications. Annu Rev Pathol 1 (2006) 151-170
2. Brody D.L., and Holtzman D.M. Active and passive immunotherapy for neurodegenerative disorders. Annu Rev Neurosci 31 (2008) 175-193
3. Papachroni K.K., Ninkina N., Papapanagiotou A., et al. Autoantibodies to alpha-synuclein in inherited Parkinson's disease. J Neurochem 101 (2007) 749-756
4. Weksler M.E., Relkin N., Turkenich R., LaRusse S., Zhou L., and Szabo P. Patients with Alzheimer disease have lower levels of serum anti-amyloid peptide antibodies than healthy elderly individuals. Exp Gerontol 37 (2002) 943-948
5. Du Y., Dodel R., Hampel H., et al. Reduced levels of amyloid ß-peptide antibody in Alzheimer's disease. Neurology 57 (2001) 801-805
6. Wei X., Wei G., Farlow M., and Du Y. Human anti-prion protein antibodies block A117V PrP peptide fibril formation and prevent A117V PrP peptide-induced neurotoxicity. Abstr Soc Neurosci 33 (2007) Program number: 12.17.2007
7. Shoenfeld Y., and Isenberg D.A. Natural autoimmunity. In: Shoenfeld Y., and Isenberg D.A. (Eds). The mosaic of autoimmunity (1989), Elsevier, Amsterdam 53-74
8. Hardy J. Has the amyloid cascade hypothesis for AD been proved?. Curr Alzheimer Res 3 (2006) 71-73
9. Schenk D. Amyloid-beta immunotherapy for AD: the end of the beginning. Nat Rev Neurosci 3 (2002) 824-828
10. Du Y., Wei X., Dodel R., et al. Human anti-beta-amyloid antibodies block beta-amyloid fibril formation and prevent beta-amyloid-induced neurotoxicity. Brain 126 (2003) 1935-1939
11. Dodel R., Du Y., Depboylu C., et al. Intravenous immunoglobulins containing antibodies against ß-amyloid for the treatment of Alzheimer's disease. J Neurol Neurosurg Psychiatry 75 (2004) 1472-1474
12. Bell R.D., Sagare A.P., Friedman A.E., et al. Transport pathways for clearance of human Alzheimer's amyloid beta-peptide and apolipoproteins E and J in the mouse central nervous system. J Cereb Blood Flow Metab 27 (2007) 909-918
13. DeMattos R.B., Bales K.R., Cummins D.J., Dodart J.C., Paul S.M., and Holtzman D.M. Peripheral anti-Ab antibody alters CNS and plasma Aß clearance and decreases brain Ab burden in a mouse model of AD. Proc Natl Acad Sci U S A 98 (2001) 8850-8855
14. N.R. Relkin P. Szabo B. Adamiak 18-Month study of intravenous immunoglobulin for treatment of mild Alzheimer disease. Neurobiol. Aging in press.
15. Tofaris G.K., and Spillantini M.G. Physiological and pathological properties of alpha-synuclein. Cell Mol Life Sci 64 (2007) 2194-2201
16. Ostrerova N., Petrucelli L., Farrer M., et al. Alpha-synuclein shares physical and functional homology with 14-3-3 proteins. J Neurosci 19 (1999) 5782-5791
17. George J.M., Jin H., Woods W.S., and Clayton D.F. Characterization of a novel protein regulated during the critical period for song learning in the zebra finch. Neuron 15 (1995) 361-372
18. Abeliovich A., Schmitz Y., Farinas I., et al. Mice lacking alpha-synuclein display functional deficits in the nigrostriatal dopamine system. Neuron 25 (2000) 239-252
19. Uversky V.N., Li J., Bower K., and Fink A.L. Synergistic effects of pesticides and metals on the fibrillation of alpha-synuclein: implications for Parkinson's disease. Neurotoxicology 23 (2002) 527-536
20. Fujiwara H., Hasegawa M., Dohmae N., et al. Alpha-synuclein is phosphorylated in synucleinopathy lesions. Nat Cell Boil 4 (2002) 160-164
21. Hodara R., Norris E.H., Giasson B.I., et al. Functional consequences of alpha-synuclein tyrosine nitration: diminished binding to lipid vesicles and increased fibril formation. J Biol Chem 279 (2004) 47746-47753
22. Volles M.J., and Lansbury Jr. P.T. Zeroing in on the pathogenic form of alpha-synuclein and its mechanism of neurotoxicity in Parkinson's disease. Biochemistry 42 (2003) 7871-7878
23. El-Agnaf O.M., Salem S.A., Paleologou K.E., et al. Detection of oligomeric forms of alpha-synuclein protein in human plasma as a potential biomarker for Parkinson's disease. Faseb J 20 (2006) 419-425
24. Masliah E., Hansen L., Adame A., et al. Abeta vaccination effects on plaque pathology in the absence of encephalitis in Alzheimer disease. Neurology 64 (2005) 129-131
25. Emadi S., Barkhordarian H., Wang M.S., Schulz P., and Sierks M.R. Isolation of a human single chain antibody fragment against oligomeric alpha-synuclein that inhibits aggregation and prevents alpha-synuclein-induced toxicity. Biol 368 (2007) 1132-1144
26. Benner E.J., Mosley R.L., Destache C.J., et al. Therapeutic immunization protects dopaminergic neurons in a mouse model of Parkinson's disease. Proc Natl Acad Sci U S A 101 (2004) 9435-9440
27. Aguzzi A., and Heikenwalder M. Pathogenesis of prion diseases: current status and future outlook. Nat Rev Microbiol 4 (2006) 765-775
28. Hu W., Rosenberg R.N., and Stuve O. Prion proteins: a biological role beyond prion diseases. Acta Neurol Scand 116 (2007) 75-82
29. Korth C., and Peters P.J. Emerging pharmacotherapies for Creutzfeldt-Jakob disease. Arch Neurol 63 (2006) 497-501
30. Enari M., Flechsig E., and Weissmann C. Scrapie prion protein accumulation by scrapie-infected neuroblastoma cells abrogated by exposure to a prion protein antibody. Proc Natl Acad Sci U S A 98 (2001) 9295-9299
31. Peretz D., Williamson R.A., Kaneko K., et al. Antibodies inhibit prion propagation and clear cell cultures of prion infectivity. Nature 412 (2001) 739-743
32. White A.R., Enever P., Tayebi M., et al. Monoclonal antibodies inhibit prion replication and delay the development of prion disease. Nature 422 (2003) 80-83
33. Wisniewski T., and Sigurdsson E.M. Therapeutic approaches for prion and AD. FEBS J 274 (2007) 3784-3798
34. Heppner F.L., Musahl C., Arrighi I., et al. Prevention of scrapie pathogenesis by transgenic expression of anti-prion protein antibodies. Science 294 (2001) 178-182
35. Handisurya A., Gilch S., Winter D., et al. Vaccination with prion peptide-displaying papillomavirus-like particles induces autoantibodies to normal prion protein that interfere with pathologic prion protein production in infected cells. Febs J 274 (2007) 1747-1758
36. Schwarz A., Kratke O., Burwinkel M., et al. Immunisation with a synthetic prion protein-derived peptide prolongs survival times of mice orally exposed to the scrapie agent. Neurosci Lett 350 (2003) 187-189
37. Bade S., and Frey A. Potential of active and passive immunizations for the prevention and therapy of transmissible spongiform encephalopathies. Expert Rev Vaccines 6 (2007) 153-168
38. Beekes M. Prions and prion diseases. FEBS J 274 (2007) 575
39. Fioriti L., Dossena S., Stewart L.R., et al. Cytosolic prion protein (PrP) is not toxic in N2a cells and primary neurons expressing pathogenic PrP mutations. J Biol Chem 280 (2005) 11320-11328
40. Brown D.R. Prion protein-overexpressing cells show altered response to a neurotoxic prion protein peptide. J Neurosci Res 54 (1998) 331-340